Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangning Huang

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
International Journal of Antimicrobial Agents|April 1, 2026
Efficacy, Safety, and Population Pharmacokinetics of Eravacycline for Carbapenem-Resistant Organism Infections in Immunocompromised Hosts: A Multicenter Prospective Cohort StudyYifu Hou, Lijuan Zhang, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
The New England Journal of Medicine|June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i>-Mutated NSCLCShun Lu, Terufumi Kato, Xiaorong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Neoadjuvant Osimertinib for Resectable <i>EGFR</i>-Mutated Non-Small Cell Lung CancerJianxing He, Masahiro Tsuboi, Walter Weder, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
International Journal of Antimicrobial Agents|April 1, 2026
Efficacy, Safety, and Population Pharmacokinetics of Eravacycline for Carbapenem-Resistant Organism Infections in Immunocompromised Hosts: A Multicenter Prospective Cohort StudyYifu Hou, Lijuan Zhang, Hong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
The New England Journal of Medicine|June 3, 2024
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i>-Mutated NSCLCShun Lu, Terufumi Kato, Xiaorong Dong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Neoadjuvant Osimertinib for Resectable <i>EGFR</i>-Mutated Non-Small Cell Lung CancerJianxing He, Masahiro Tsuboi, Walter Weder, et al.
Pageof 6